Bibliography
Found 59 results
Filters: Author is McCutchan, J Allen [Clear All Filters]
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013 ;24(5):351-5.
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 ;59(4):376-81.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons. J Neuropsychiatry Clin Neurosci. 2011 ;23(3):316-23.
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 ;17(1):3-16.
Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr. 2011 ;58(2):154-62.
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. 2011 ;33(5):505-22.
Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009 ;23(17):2317-22.
. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain: A Journal of Neurology [Internet]. 2006 ;129:1872-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16735456
Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. Journal of Neurovirology [Internet]. 2006 ;12:100-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16798671
. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. Journal of Neuroimmunology [Internet]. 2006 ;179:180-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16901548
. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. Journal of NeuroVirology [Internet]. 2005 ;11(4):356-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16206458
Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. Journal of Neuroimmunology [Internet]. 2005 ;169(1-2):144-52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16182380
. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (London, England) [Internet]. 2005 ;19 Suppl 3:S72-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16251831
. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. Journal of Virology [Internet]. 2005 ;79(3):1772-88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15650202